PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 39/00, A61P 35/00	A2	(11) International Publication Number: WO 00/33870
		(43) International Publication Date: 15 June 2000 (15.06.00)

(21) International Application Number: PCT/GB99/04135

(22) International Filing Date: 9 December 1999 (09.12.99)

(30) Priority Data:
9827103.4 10 December 1998 (10.12.98) GB

(71) Applicant *(for all designated States except US)*: ONYVAX LIMITED [GB/GB]; P.O. Box 17717, St. Georges Hospital Medical School, Cranmer Terrace, London SW17 0WG (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: DALGLEISH, Angus, George [GB/GB]; Onyvax Limited, P.O. Box 17717, St. Georges Hospital Medical School, Cranmer Terrace, London SW17 0WG (GB). SMITH, Peter, Michael [GB/GB]; Onyvax Limited, P.O. Box 17717, St. Georges Hospital Medical School, Cranmer Terrace, London SW17 0WG (GB). SUTTON, Andrew, Derek [GB/GB]; Onyvax Limited, P.O. Box 17717, St. Georges Hospital Medical School, Cranmer Terrace, London SW17 0WG (GB). WALKER, Anthony, Ian [GB/GB]; Onyvax Limited, P.O. Box 17717, St. Georges Hospital Medical School, Cranmer Terrace, London SW17 0WG (GB).

(74) Agent: DAVIES, Jonathan, Mark; Reddie & Grose, 16 Theobalds Road, London WCLX 8PL (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: NEW CANCER TREATMENTS

(57) Abstract

The invention relates to a product comprised of specific combinations of cell lines intended for use as an allogeneic immunotherapy agent for the treatment of prostate cancer in humans. The heterogeneity of the immunotherapeutic matches the heterogeneity of the antigenic profile in the target prostate cancer and immunises the recipients with many of the potential TAA and TSA which are expressed at various stages of the disease. The invention discloses a vaccine comprising a combination of three different cell lines prepared from primary or metastatic prostate cancer biopsy material. The cell lines are lethally irradiated utilising gamma irradiation at 50–300 Gy to ensure that they are replication incompetent.